ArticleClinical kidney journal2012
Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis.
Article in Clinical kidney journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.Pediatric nephrology (Berlin, Germany) · 2019Review
- Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?Clinical kidney journal · 2017Article
- Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.Clinical and experimental nephrology · 2016Article
- Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab.BMJ case reports · 2016Article
- An international consensus approach to the management of atypical hemolytic uremic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2016Review
- Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.Clinical nephrology · 2015Article
- Timing of eculizumab therapy for C3 glomerulonephritis.Clinical kidney journal · 2015Article
- Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension.Pediatric nephrology (Berlin, Germany) · 2015Article
- Successful treatment of DEAP-HUS with eculizumab.Pediatric nephrology (Berlin, Germany) · 2014Article
- Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Molecular immunology · 2013Review
- Atypical hemolytic uremic syndrome.Seminars in nephrology · 2013Review
- Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Nature reviews. Nephrology · 2012Review
- Treatment of atypical uraemic syndrome in the era of eculizumab.Clinical kidney journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disorders in complement regulation are a major cause of atypical haemolytic-uraemic syndrome (aHUS). Eculizumab, a monoclonal antibody targeting complement C5 and blocking the terminal complement cascade, should theoretically be useful in this disease, particularly when associated with specific complement pathway anomalies such as Factor H deficiency. Eculizumab is emerging as an effective treatment for post-transplant aHUS recurrence and may have a role in treating de novo aHUS, halting the haemolytic process. In this case report, we describe the fourth case of aHUS treated with eculizumab. In our patient, with a known complement Factor H mutation, not only has the disease process become quiescent but also this therapy has led to significantly improved renal function so that dialysis is no longer necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.